Harold Elliot Varmus, M.D.

Medical Education UC Berkeley, NIH, Sloan Kettering 
Medical Oncology
"Harold Varmus"

The Nobel Prize in Physiology or Medicine 1989 was awarded jointly to J. Michael Bishop and Harold E. Varmus "for their discovery of the cellular origin of retroviral oncogenes"


Sign in to add mentor
J. Michael Bishop post-doc 1970-1972 UC Berkeley / UCSF (FlyTree)
Ira Pastan research scientist 1968-1970 NIH (Neurotree)
Mike Fried research scientist 1978-1979 Imperial Cancer Research Fund (Cell Biology Tree)


Sign in to add trainee
Tyler Jacks grad student UCSF (Cell Biology Tree)
Peter Pryciak grad student (Neurotree)
Gregory S. Payne grad student 1982 UCSF (Cell Biology Tree)
Joshua M. Kaplan grad student 1986-1990 UCSF (Neurotree)
Kari Alitalo post-doc UCSF (Cell Biology Tree)
Donald E. Ganem post-doc UCSF (Cell Biology Tree)
Roeland Nusse post-doc UCSF (Chemistry Tree)
Sandra Orsulic post-doc
Rolf Sprengel post-doc (Neurotree)
John A. T. Young post-doc UCSF (ID Tree)
Chi Van Dang post-doc 1978-1982 UCSF
Patrick O. Brown post-doc 1985-1988 UCSF (FlyTree)
Titia de Lange post-doc 1985-1990 UC Berkeley (Telomere and Telomerase Tree)
Pamela L. Schwartzberg post-doc 1995-1999 NIH (Chemistry Tree)
Eric Holland post-doc 1996-1999 NIH
Bart O Williams post-doc 1996-1999 National Cancer Institue-NIH (Neurotree)
Yi Li post-doc 1997-2002 NIH, Sloan Kettering
Katerina A. Politi post-doc 2003-2009 Memorial Sloan-Kettering Cancer Center (Cell Biology Tree)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Maity TK, Venugopalan A, Linnoila I, et al. (2015) Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. Cancer Discovery. 5: 534-49
Collins FS, Varmus H. (2015) A new initiative on precision medicine New England Journal of Medicine. 372: 793-795
Abrams J, Kramer B, Doroshow JH, et al. (2015) National Cancer Institute-supported clinical trials networks. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 293
Unni AM, Lockwood WW, Zejnullahu K, et al. (2015) Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma Elife. 4: 1-23
Alberts B, Kirschner MW, Tilghman S, et al. (2014) Rescuing US biomedical research from its systemic flaws. Proceedings of the National Academy of Sciences of the United States of America. 111: 5773-7
de Bruin EC, Cowell C, Warne PH, et al. (2014) Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discovery. 4: 606-19
Berger AH, Chen M, Morotti A, et al. (2013) DOK2 inhibits EGFR-mutated lung adenocarcinoma. Plos One. 8: e79526
Varmus H, Kumar HS. (2013) Addressing the growing international challenge of cancer: A multinational perspective Science Translational Medicine. 5
Sacco RL, Smith SC, Holmes D, et al. (2013) Accelerating progress on non-communicable diseases The Lancet. 382: e4-e5
Lockwood WW, Zejnullahu K, Bradner JE, et al. (2012) Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins Proceedings of the National Academy of Sciences of the United States of America. 109: 19408-19413
See more...